Progression-free survival. (A) PFS in phase 2 patients refractory (N = 18) or relapsed (N = 37) after lenalidomide. (B) PFS in phase 2 patients according to best response (treated as time-dependent covariate). (C) PFS in phase 2 patients with standard-risk or high-risk FISH abnormalities.